Skip to main content
Fig. 2 | The Ultrasound Journal

Fig. 2

From: The diagnostic accuracy of lung ultrasound to determine PiCCO-derived extravascular lung water in invasively ventilated patients with COVID-19 ARDS

Fig. 2

Flowchart of the inclusion and exclusion process. Due to logistic reasons, lung ultrasound (LUS) was only performed in 2 of the 4 centers participating in the InventCOVID trial (Amsterdam UMC, locations AMC and VUMC), resulting in LUS exams performed in 33 patients. Of these, 3 LUS exams were lost due to image recording errors. After the exclusion of exams missing > 4 regions, 26 patients had LUS data on study day 1 (= time point 1, within 48 hours after intubation) and 24 patients had LUS data on study day 4 (= time point 2). InventCOVID trial: the efficacy and safety of intravenous imatinib in invasively ventilated patients with moderate-to-severe COVID-19-related ARDS

Back to article page